Hemostatic Single 8 Gy radiotherapy for Tumor bleeding Palliation

Hemostatic Single 8 Gy radiotherapy for Tumor bleeding Palliation - HemoStop Study

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000059654

Enrollment

100

Registered

2025-11-06

Start date

2025-02-17

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

All cancers with tumor-related bleeding

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) Patients scheduled to receive radiotherapy with a single 8 Gy fraction for tumor-related bleeding 2) Patients aged 20 years or older at the time of obtaining consent 3) Patients who have provided oral informed consent

Exclusion criteria

Exclusion criteria: 1) Patients for whom follow-up is expected to be difficult (e.g., those living far from the hospital or with a performance status of 4 or higher)

Design outcomes

Primary

Measure	Time frame
Hemostatic response rate	—

Secondary

Measure	Time frame
rebleeding rate, time to first rebleeding, overall survival	—

Countries

Japan

Contacts

Public ContactKenji Makita

National Cancer Center Hospital East Department of Radiation Oncology

kemaki3@east.ncc.go.jp0471331111

Outcome results